Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine

  • STATUS
    Recruiting
  • End date
    Dec 31, 2022
  • participants needed
    900
  • sponsor
    University of Oxford
Updated on 4 September 2021

Summary

In the recent past there has been a number of large urban Yellow Fever outbreaks in sub-Saharan Africa, tropical South Americas, The demand for Yellow Fever vaccines in response to the large urban outbreaks occurring concurrently and the risk of further spread through Africa and to Asia was larger than the available global supply. In this situation, the World Health Organisation (WHO) developed recommendations for the use of fractional doses of Yellow Fever vaccine as a dose-sparing strategy. These recommendations were based on data from a limited number of clinical trials, none of which had been conducted in Africa. This was due to the uncertainties on the minimum dose requirement.

Our study complements a study which is comparing full standard dose to 1/5th of standard dose of all four WHO-prequalified YF vaccines in adults (ClinicalTrials.gov number: NCT02991495), and is currently ongoing at KEMRI CGMRC and Epicentre, Mbarara which is designed to answer questions on the use of current stock of YF vaccines with a potency as close as possible to each manufacturers' minimum release. Data from this trial will inform a WHO recommendation on using 1/5th of the current standard dose of vaccine for outbreak control. However, since many vials will contain excess YF vaccine such that 1/5th of a vial is likely to be substantially above the current minimum potency requirements, these data may not be scientifically explanatory regarding the minimum dose required for preventive use.

The new complementary study, aims to determine the lowest YF vaccine dose that is non-inferior to the current standard full dose among populations in sub-Saharan Africa. The study will be conducted in Kenya (KEMRI Center for Geographical Medicine Research-Coast (CGMR-C), Kilifi) and Uganda (Epicentre, Mbarara) with trial participants recruited at both sites, using vaccine from one WHO-prequalified manufacturer (Institut Pasteur de Dakar, Senegal (IPD)).

Description

Yellow fever (YF) is a disease caused by a mosquito-borne flavivirus that is endemic in sub-Saharan Africa and tropical South America. Ninety percent of YF cases are in Africa where YF virus is transmitted by different mosquito genera in three recognized transmission cycles. A sylvatic cycle involves transmission between forest-dwelling mosquitoes (Haemagogus spp) and non-human primate reservoirs, with sporadic incidental transmission to humans (e.g. forest workers). An intermediate cycle, occurring only in Africa, involves mosquito transmission between non-human primates and humans, or human-to-human transmission among humans living or working close to forested areas. An urban cycle involves transmission between humans and urban mosquito vectors, primarily Aedes aegypti, and occurs when a viraemic person, infected in the sylvatic or intermediate cycle, introduces YF virus to areas with a large non-immune population and A. aegypti vectors resulting in disease outbreaks.

Infection with YF virus is characterised by a wide range of manifestations, ranging from subclinical infection with mild and non-specific symptoms, to severe, life-threatening illness with jaundice, renal failure and haemorrhage.

A highly effective vaccine is available for use against YF in adults and children aged 9 months. The vaccine is a freeze-dried preparation of live attenuated YF virus strain 17D, which was developed in 1937 and is produced by four WHO-prequalified manufacturers. A single dose of YF vaccine is considered sufficient to confer life-long protective immunity against all seven known genotypes of wild-type YF virus. Protective levels of YF virus neutralizing antibodies are developed in 80-100% vaccine recipients within 10 days after vaccination, and in 99% within a month.

Although fractional dosing has recently been used in vaccination campaigns in Kinshasa and Brazil in 2016, 2017 and 2018, WHO recommendations were based on a limited number of clinical studies and important data gaps remain.

fractional vaccine dosing is compounded by the uncertainty surrounding minimum dose requirements.

This study therefore aims to determine the lowest dose in International Units (IU/dose) that is non-inferior to the standard full dose among populations in sub-Saharan Africa. The data generated in this study will provide information regarding the re-definition of the minimal dose and potency requirements of the vaccine. The study will also provide further confidence in the use of fractional doses of YF vaccine during epidemics. In addition, the investigators will assess the range of views and perceptions of key stakeholders in vaccine policy and implementation on reduced vaccine dose usage during YF epidemics and for routine use.

. The study will be conducted at the KEMRI CGMRC in Kilifi, Kenya and at Epicentre in Mbarara, Uganda. Both these sites are already working together in an ongoing study (ClinicalTrials.gov number: NCT02991495).

Adult participants (n=480) will be randomized for vaccination with full standard dose or with 1000, 500 or 250 IU (i.e. 4 arms) with a 1:1:1:1 allocation ratio. Results for the safety and primary outcome of the adult study will then be reviewed by the DSMB, and the lowest non-inferior dose in the adult study selected for assessment in children aged 9 months to 5 years (n=420) in comparison to full standard dose (i.e. 2 arms) with a 1:1 allocation ratio. The determination of the non-inferior dose to use in children will be made by the sponsor in discussion with the study Data Safety and Monitoring Board (DSMB), vaccine manufacturer and relevant stakeholders, and the final decision communicated to the various regulatory authorities as a notification (i.e. Scientific and Ethics Review Board (SERU) at KEMRI, Oxford Tropical Research Ethics Committee (OxTREC) and Pharmacy and Poisons board (PPB) for the Kilifi site, Mbarara University of Science and Technology's Research Ethics Committee (MUST-REC), Uganda National Council of Science and Technology (UNCST) and National Drug Authority (NDA) for the Mbarara site).

Adult vaccinees will be followed up for 2 years, and children for 1 year. There will be no gradual age de-escalation on the basis that there are few safety concerns with the full dose of YF vaccines, having been used in millions of children worldwide.

Details
Condition Yellow Fever Vaccine, Yellow Fever
Treatment Yellow fever vaccine, Institut Pasteur
Clinical Study IdentifierNCT04059471
SponsorUniversity of Oxford
Last Modified on4 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Individuals aged 18 - <60 years of age
Children aged between 9 months and 12 months
HIV negative on serological screening OR HIV positive adults and children aged > 18 months on serological testing, and no symptoms suggestive of current clinical immunosuppression and cluster of differentiation-4 (CD4) count>200 (for adults) and CD4% > 25% (for children aged 9-12 months) within the last 6 months
Ability to provide informed consent to participate in the study

Exclusion Criteria

Known contraindications to YF vaccination such as allergies to egg protein and chicken products or any component of the vaccine (including gelatin, eggs, eggs products or chicken products), immunodeficiency, known thymus disorder, such as thymoma and myasthenia gravis
Using corticosteroids or other immunosuppressive therapy
Thymus disorder, such as thymoma and myasthenia gravis
Acute febrile disease on the day of vaccination with temperature >37.5 degrees Celsius is a temporal contraindication
Previous YF vaccination
Previous YF infection as determined from history
Pregnancy (as determined by a urine test on the proposed day of vaccination) and lactating women
Planning to migrate out of the study areas before the end of the study follow-up
Planning to travel to a country requiring YF vaccination certificate within the first year after vaccination
Any condition or criteria, including acute or chronic clinically significant abnormality that in the opinion of the investigator might compromise the wellbeing of the volunteer or interfere with the outcome of the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note